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The challenges of introducing routine
G6PD testing into radical cure: a workshop
report
Benedikt Ley1*†, Nick Luter2†, Fe Esperanza Espino3, Angela Devine4,6, Michael Kalnoky2, Yoel Lubell3,6,
Kamala Thriemer1, J. Kevin Baird5,6, Eugenie Poirot7, Nolwenn Conan8, Chong Chee Kheong9, Lek Dysoley10,11,
Wasif Ali Khan12, April G. Dion‑Berboso13, Germana Bancone14, Jimee Hwang7,15, Ritu Kumar2, Ric N. Price1,6,
Lorenz von Seidlein4,6 and Gonzalo J. Domingo2

Abstract
The only currently available drug that effectively removes malaria hypnozoites from the human host is primaquine.
The use of 8-aminoquinolines is hampered by haemolytic side effects in glucose-6-phosphate dehydrogenase (G6PD)
deficient individuals. Recently a number of qualitative and a quantitative rapid diagnostic test (RDT) format have been
developed that provide an alternative to the current standard G6PD activity assays. The WHO has recently recom‑
mended routine testing of G6PD status prior to primaquine radical cure whenever possible. A workshop was held in
the Philippines in early 2015 to discuss key challenges and knowledge gaps that hinder the introduction of routine
G6PD testing. Two point-of-care (PoC) test formats for the measurement of G6PD activity are currently available:
qualitative tests comparable to malaria RDT as well as biosensors that provide a quantitative reading. Qualitative G6PD
PoC tests provide a binomial test result, are easy to use and some products are comparable in price to the widely used
fluorescent spot test. Qualitative test results can accurately classify hemizygous males, heterozygous females, but may
misclassify females with intermediate G6PD activity. Biosensors provide a more complex quantitative readout and are
better suited to identify heterozygous females. While associated with higher costs per sample tested biosensors have
the potential for broader use in other scenarios where knowledge of G6PD activity is relevant as well. The introduc‑
tion of routine G6PD testing is associated with additional costs on top of routine treatment that will vary by setting
and will need to be assessed prior to test introduction. Reliable G6PD PoC tests have the potential to play an essential
role in future malaria elimination programmes, however require an improved understanding on how to best integrate
routine G6PD testing into different health settings.
Keywords: G6PD, Point of care test, Plasmodium vivax, Primaquine, Malaria
Introduction
Plasmodium vivax has long been considered a benign
form of malaria, but this paradigm is changing. Vivax
malaria can have a profound impact on health, particularly in women and children from poorly resourced
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communities [1–3]. Successful control and ultimate
elimination of P. vivax will require a radical cure, that
combines a schizontocide to eliminate blood stages of
the parasite and a hypnozoiticide to kill the liver stages.
Primaquine, an 8-aminoquinoline (8-AQ), is the only
widely available hypnozoiticide [4], although a new,
slowly eliminated 8-aminoquinoline, tafenoquine is currently in Phase III clinical trials [5]. Although 8-aminoquinolones are well tolerated by most individuals [6],
this class of drugs can trigger haemolytic reactions in
glucose-6-phosphate dehydrogenase (G6PD) deficient
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recipients [7]. The risk of drug induced haemolysis in
relatively small G6PD deficient subpopulations needs
to be balanced with the risk of anaemia and other detrimental effects due to recurrent episodes of malaria in
all vivax patients. Reliable, easy to perform point-of-care
(PoC) tests provide a potential solution to this dilemma.
If G6PD status can be assessed before commencing radical cure treatment, the threat of severe side effects from
primaquine can be minimized in the at-risk population.
For several decades the research agenda for radical cure
has been neglected and the demand for reliable, easy-touse G6PD tests has not been a priority. In the last decade malaria control and elimination programmes have
gained considerable momentum, particularly in reducing the burden of P. falciparum. Increasingly the need
for an improved management of P. vivax is recognized
as a programmatic priority. Based on the experience in
G6PD deficient African American soldiers, radical cure
with primaquine was long considered safe; however, the
potential risks in more severe variants of G6PD deficiency can be considerable. In the most recent WHO
treatment guidelines G6PD testing to guide radical cure
is recommended whenever possible [8]. When testing is
not possible the risks and benefits of primaquine treatment must be weighed prior to drug administration.
The administration of a single low dose of 0.25 mg/kg
bw primaquine to kill P. falciparum gametocytes is considered unlikely to cause serious toxicity even in people
with G6PD deficiency [8] and G6PD testing is not recommended prior to the administration of a single low dose.
Since 2012 a series of workshops have been held by
the Asia Pacific Malaria Elimination Network (APMEN)
to discuss G6PD testing in the context of vivax malaria
treatment in the Asia Pacific. The first workshop of this
series was held in Incheon, South Korea in May 2012,
where the research agenda for G6PD deficiency and the
radical cure of P. vivax was reviewed, an update of available tests presented, and a target product profile for a
point-of-care test for G6PD deficiency proposed [7]. The
focus of the second workshop in October 2012 in Bangkok, Thailand was on use—case scenarios, updating the
target product profile for point-of-care tests, and discussing criteria for their evaluation [9].
This article reports on the third workshop held at the
Research Institute of Tropical Medicine (RITM), the
Philippines, in February 2015, in a joint effort by the Asia
Pacific Malaria Elimination Network (APMEN), RITM
and PATH. Main objectives of the workshop were on the
challenges and evidence gaps facing successful implementation of G6PD screening in the context of currently
available and anticipated point-of-care tests for G6PD
deficiency. The workshop included participants from
Australia, Bangladesh, Cambodia, Indonesia, Malaysia,
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the Philippines, Thailand, UK, US and Vietnam, representing research institutions and country malaria control
programmes. The discussion was timely in the context
of the most recent recommendations emerging from the
2014 WHO expert review group on G6PD deficiency
[10], the resulting guidance from the March 2015 WHO
Malaria Policy Advisory Committee and the recently
published malaria treatment guidelines by the WHO [8].

Background
Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme in the pentose phosphate pathway which is
the sole source of energy for red blood cells (RBCs) and
the only mechanism to maintain the cells redox potential
[11]. In contrast to other human cells, RBCs do not have
a nucleus and are hence reliant on the enzyme molecules
provided during erythropoiesis. As a result the life expectancy of healthy RBCs under normal circumstances is
comparably short at around 120 days [12].
Intracellular enzyme activity in RBCs is a function of
the initial abundance of the enzyme, enzyme half-life
and the RBC half-life. G6PD deficiency (G6PDd) is the
result of a structural defect of the G6PD enzyme and is
one of the most common enzymopathies worldwide [13,
14]. G6PD deficiencies vary from slightly reduced G6PD
activities to extremely low G6PD activity even in young
RBCs, while the absence of enzyme activity is not compatible with human life [15]. In 1989, the WHO G6PD
working group proposed to categorize G6PDd into
classes I–V [16] based on measured activity relative to
normal G6PD activity (in percent). Defining an absolute
quantitative 100 % G6PD activity is challenging due to its
dependence on the population under consideration, the
assay conditions and assay platform. Current definitions
are population specific and based on the median G6PD

Table 1 Calculating G6PD activity
The WHO has defined a total of five classes (I–V) of G6PD activity [16]:
• Severe deficiency (<10 % activity, chronic, non-spherocytic, haemolytic
anaemia)
• Severe deficiency (<10 % activity, intermittent haemolysis)
• Mild deficiency (10–60 % activity, haemolysis with stressors only)
• Normal enzyme variant (60–150 % activity, no clinical sequelae)
• Increased enzyme activity (>150 % activity, no clinical sequelae)
100 % G6PD activity is based on the adjusted quantitative (iU/gHb or
U/1012 RBC) median of all male samples from a defined sample set
[9]. In a first step the median G6PD activity of samples from all male
participants is calculated. Second, all samples with ≤10 % G6PD activity
of the median are excluded. Third, the median is re-calculated based on
the remaining samples, the adjusted male median. The adjusted male
median is defined as 100 % G6PD activity and all samples are grouped
accordingly
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activity of all males excluding those that are hemizygous
G6PD deficient (Table 1) [9].
The underlying G6PD gene is located on the X-chromosome (Xq28), spans a total length of 18.5 kb and
includes 13 exons and 12 introns [17]. More than 185
G6PD mutations have been described to date [18] giving
rise to hemizygous men as well as homozygous and heterozygous women, the latter possessing two distinct populations of RBCs. In heterozygous females G6PD normal
and G6PD deficient RBCs co-exist in varying proportions determined by random X-chromosome inactivation
(lyonization) [7].
Higher G6PD prevalence rates appear more commonly where higher rates of malaria transmission occur.
Such trends may be directly related to protection against
severe malaria conferred by some variants of G6PDd
[19–22]. G6PDd affects approximately 400 million people worldwide [23]. Manifestations can include neonatal
jaundice, favism and haemolytic anemia but in the vast
majority of G6PD deficient cases quality of life is not
affected and G6PD deficient people may not even be
aware of their condition. However in the presence of oxidizing agents the reduced activity of the G6PD enzyme
results in a dis-balanced redox equilibrium of the RBC
and ultimate destruction of the cell, i.e. haemolysis [21].
Numerous compounds can induce haemolysis in G6PDd
RBCs including 8-aminoquinoline based anti-malarial
drugs [24].
Quantitative versus qualitative test formats

Diagnostic assays can be grouped into genotypic assays,
sequencing methods as well as phenotypic test assays
[7]. Genotypic assays and sequencing methods can provide a precise option for diagnosing G6PD mutations
but require long and complicated test procedures, a
well-equipped laboratory and highly trained staff [25,
26]. Phenotypic tests can be grouped into qualitative,
quantitative and cytochemical test assays. Phenotypic
tests are based on the direct or indirect detection of
NADPH + H+, formed as a result of G6PD activity [11].
Qualitative test formats indicate activity above a test’s
inherent activity threshold level. While qualitative test
formats are easier to perform and interpret compared
to quantitative test methods and cytochemical tests, the
reduction of a quantitative phenomenon (G6PD activity) to a binominal outcome is problematic. For technical reasons, current qualitative tests can only accurately
diagnose G6PDd in people with G6PD activity below
30–40 % normal activity [27–29]. While this accurately
identifies all hemizygous G6PDd males and homozygous
G6PDd females, females with heterozygous G6PD alleles
are not accurately discriminated. G6PD normal and
G6PDd red blood cell (RBC) populations can co-exist
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within a heterozygous female [7]. In these women, G6PD
normal RBCs may mask G6PD deficient cell populations
and can result in G6PD normal test results [27, 30–32].
Currently, the relationship between G6PD activity and
degree of drug induced haemolysis is poorly understood
and varies depending on the haemolytic potential of the
applied drug [21].
A quantitative test assay will accommodate different
threshold activities and within limits is able to identify
heterozygous females as individuals with intermediate
G6PD activity (as a result of G6PD normal and G6PD
deficient cell populations). Most quantitative test assays
to date require a good laboratory infrastructure and welltrained staff. Handheld devices that do not rely on laboratory infrastructure and can provide results within several
minutes are currently being introduced but require further evaluation before treatment decisions can be based
on these devices.
Only cytochemical assays can effectively distinguish
between G6PD normal and G6PD deficient RBCs on a
cellular level and can effectively identify heterozygous
women with a high percentage of G6PDd red blood cells
that are accordingly at risk for severe haemolysis [33].
There are flow cytometry-based assays that allow the
measurement of G6PD activity in labelled RBCs [34].
The main drawbacks of this format are the complexity
of the respective test assays and interpretation, the need
for costly machinery and the long turn-around time that
make these assays unsuitable for PoC testing.
Product options for point‑of‑care G6PD testing

For many years the Fluorescent Spot Test (FST) was the
only available PoC for G6PD testing. The inherent limitations of the FST include the requirement of basic lab
facilities (refrigeration, a water bath, and UV light), the
qualitative nature of the test and the need for significant
upfront training of the test users [35]. In recent years
novel technologies are changing the landscape [29, 36,
37]. Included in these new technologies are three PoC
devices (Table 2).
Two companies, Accessbio (New Jersey, USA) and
Alere (Maine, USA), have developed different types of
PoC diagnostics for G6PD deficiency that focus on rapid
diagnosis, with limited need for technical training and
infrastructure [28, 35]. Both companies have created
qualitative RDTs. In addition to the RDT, CareStart has
also produced a quantitative biosensor reader, which is
currently under evaluation in several field sites.
The format of the qualitative, lateral flow RDT is similar to many malaria RDTs on the market. In contrast to
the detection of Plasmodium antigens the G6PD RDT is
based on the reduction of colourless nitro blue tetrazolium dye to dark coloured formazan [38]. The appearance

5–7 min

5
4 min

Medium

Medium–high

Medium–high

Medium

Low

Through-put
capacity

Not specified but
likely broad

18°–25 °C

Not specified

37 °C

20°–39 °C

Working
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Not specified
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3 days at 2°–8 °C, or
frozen

1 week at 2°–8 °C

1 week at 2°–8 °C
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preservation
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$500 for Biosensor,
$2.50 per test
strip

$20.00

$1.50

~$3.00

$10.00*

Price
of product

* Price varies according to number of samples run/control and number of runs performed/sample

Sources: Price information for Trinity G-6-PDH and CareStart G6PD RDT based on von Fricken et al. [53]. Carestart G6PD RDT and Carestart Biosensor confirmed via correspondence with Accessbio. BinaxNow price is
from correspondence with Alere©. Trinity FST is an estimated price per use based on recent PATH purchases. End prices to user will vary widely based on local distributor pricing and in the case of the assay kits (FST and
spectrophotometry) individual laboratory sample through put and workflow

1

15°–30 °C and low

BinaxNOW G6PD test

CareStart G6PD biosen‑ Only needle for finger stick Not provided and low
sor test

Pipettes, timer

5–10 min

3

Not provided and low

CareStart G6PD screen‑ Pipettes, timer
ing Test

25–30 min

15–25 min

Total time
to result

5

Number of
steps for sample
prep

Trinity fluorescent spot UV light with dark room
2°–8 °C and moderate
test (FST)
or viewing box, pipettes,
timer

Kit storage temp.
and complexity
8

Resource requirements
(equipment,
infrastructure, etc.).

Trinity G-6-PDH (kinetic Electricity, spectropho‑
2°–8 °C and high
spectrophotometry)
tometer with temp. con‑
trol, pipettes, deionized
water, timer, water bath
(optional)

Test name

Table 2 Summary specifications for a subset of commercially available G6PD Tests
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of a purple/blue coloration indicates a G6PD normal
result. While the BinaxNOW G6PD test (Alere, USA),
available since 2008, has good performance in controlled
laboratory settings [27, 37] performance of this test in
less controlled settings was less satisfactory [39]. In 2013,
Accessbio (USA) released the CareStart G6PD test onto
the market. Recent studies have indicated that the CareStart G6PD test is non-inferior in the diagnosis of G6PD
deficiency to the FST [28]. Furthermore, field studies in
Cambodia have indicated that the CareStart G6PD RDT
is capable of reliably detecting G6PD deficient individuals with enzyme activity levels <30 % of normal activity
[29]. However, the current Carestart G6PD RDT does not
include a control-line, a short-coming that affects result
validity.
Biosensors, the second type of PoC device developed,
are handheld devices that in conjunction with a disposable strip provide a quantitative result. These tests
directly measure G6PD activity from collected blood
based on electro-chemical properties of the sample. In
2015, AccessBio (USA) launched the CareStart Biosensor, which at present, is the only product of this type on
the market. The test is similar to a glucometer common
in many developed country markets. The biosensor has
a quantitative readout of G6PD activity and provides a
number of advantages over a qualitative RDT, including the possibility to design malaria treatment schemes
based on the test readout, the ability to use readouts
for drugs outside of 8-aminoquinolines and improved
identification of heterozygous females with intermediate G6PD activity. The device has not been validated
to date and is limited by the absence of an integrated
haemoglobin Hb reader which is required for the estimation of IU/g Hb. These are exciting and over-due
new offerings in the G6PD testing product pipeline,
but compared to malaria or HIV RDTs, the pipeline
remains very thin.
Favorable environments for different test options

When G6PD status is unknown and G6PD testing is
not available, the 2015 WHO treatment guidelines suggest to base the decision to prescribe primaquine on an
assessment of the risks and benefits of the treatment [8].
The ethical implications of primaquine therapy against
malaria transmission and G6PD testing have been discussed recently and are beyond the scope of this report
[40]. The risks of treatment are reduced under several conditions such as a low prevalence of G6PDd, the
absence of G6PD variants associated with severe haemolysis [41], and the absence of sub-populations at an
increased risk of drug induced haemolysis. The benefits
of radical cure are also likely to vary, depending on factors such as the patient profile, as well as the vivax strain
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and its associated probability and frequency of relapse.
Finally, close follow-up of all patients receiving treatment must be feasible and facilities to respond to severe
haemolytic reactions must be available. Where the clinical benefits of radical cure are assumed to outweigh the
risk of haemolysis, the cost implications of treating rare
haemolytic events should also be balanced against the
cost savings from relapses avoided.
In reality, even where the risk/benefit ratio and economic considerations would suggest that radical cure is
advised without G6PD testing, clinicians often refrain
from prescribing primaquine. There is a strong argument
therefore to advocate G6PD testing more universally.
Routine testing using both the RDT and biosensor in
point-of-care situations prior to vivax treatment has
advantages but also risks. Based on strengths and weaknesses, three test and treat algorithms can be considered
(Figs. 1, 2, 3).
Scenario 1

G6PD RDT (Fig. 1): The qualitative RDT provides a
binary result that can be used at almost any level of the
health system and requires little training. The RDT is
well suited to discriminate homozygous and hemizygous
G6PD deficient and G6PD normal males, but cannot
identify heterozygous females, putting these women at
increased risk for a potentially false normal G6PD result.
All women testing G6PD normal by the RDT treated
according to WHO treatment guidelines for radical cure
in G6PD normal individuals [8] should be monitored
for haemolysis during the first 7 days of treatment [42];
alternatively they can be treated with the 8 week 45 mg
primaquine/week regimen as recommended for G6PD
deficient individuals [8, 10]. RDT formats with a comparable performance as the FST [28] have the potential to
replace the latter in settings where the FST is currently
in use due to superior operational characteristics, such
as a faster turn-around time and no need for additional
instrumentation or refrigeration.
Scenario 2

G6PD Biosensor (Fig. 2): The Biosensor can rapidly provide a quantitative result on G6PD activity, and potentially allows identifying heterozygous women. All female
patients with a Biosensor based G6PD normal results
can undergo radical cure as recommended by the WHO
[8] without further precautionary measures. Any patient
identified as G6PD intermediate or deficient will require
a prolonged course of treatment [8]. While the broad
use of the Biosensor may appear ideal considering the
increased treatment safety for female patients, it may
come at a greater cost and the need additional technical training. In order for the Biosensor to be effective,
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Fig. 1 G6PD qualitative RDT only

Fig. 2 G6PD quantitative biosensor only

sound knowledge of G6PD threshold activities for different drugs and G6PD variants, as well as a universally
applicable quantitative definition of G6PD deficiency

may be needed; however, a hand held device can be programmed to provide a simple interpretation of the result
and whether to provide treatment.
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Fig. 3 G6PD qualitative RDT and quantitative biosensor

Scenario 3

Combined use of RDT and Biosensor (Fig. 3): The combined product scenario creates the potential for a system in which all male patients are tested with the RDT
and the result is directly translated into a radical cure
treatment scheme according to WHO guidelines [8]. All
female patients are tested with the Biosensor to identify
heterozygous females and treated with a prolonged primaquine regimen [8].
Irrespective of the applied test format to determine
G6PD status, prolonged primaquine courses are usually
reserved for patients with mild to moderate G6PD deficiency and only if appropriate monitoring and facilities
are available to respond to severe haemolytic reactions
[43].
Economics of testing for G6PD deficiency

The burden of P. vivax is difficult to determine for a variety of reasons. Firstly, cases often happen in areas where
there are poor health care systems. Indirect costs of disease include lost productivity and transport to the health
care facilities. Each relapse results in at least 3 days off
work [1]. Time off work can contribute to poverty and
malnutrition. In addition, recurrent disease makes people more vulnerable to anemia and other diseases. It is
also challenging to differentiate between primary episodes and relapses; in some areas it has been found that
the majority of cases are relapses while in other areas

primary infections are the lion’s share of the total burden
[44, 45]. This confounds the understanding of the burden
of disease as well as the potential impact of interventions
to mitigate its effects.
G6PD testing can enable the wider use of primaquine
to prevent relapses in areas where it is not used for fear
of haemolysis. In areas that give out primaquine without
knowledge of G6PD status, G6PD testing can enable the
safer use of primaquine. Testing for G6PD deficiency and
the selection of a specific test format prior to therapeutic
decisions will have cost implications (Additional file 1). In
addition to the aforementioned indirect costs, the direct
costs will include the basic commodity costs, distribution
costs, training costs, and human resource costs. G6PD
testing will have direct and indirect effects on P. vivax
malaria burden. By facilitating the use of primaquine the
direct effects include (relapse) episodes of vivax averted
and the costs associated with these. The indirect effects
include the prevention of transmission, decreasing the
incidence of new P. vivax infections. These are difficult to
quantify due to our limited understanding of hypnozoites
and the effect is likely to be highly heterogeneous.
Cost‑effectiveness models

Economic modelling can be used to look at the long-term
costs and outcomes of G6PD screening and primaquine
use. For P. vivax, these models might include decision
trees to look at the outcome of a single episode, which
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can be extended to Markov models to look at the impact
of primaquine on recurrent episodes, or dynamic transmission models to investigate the impact of primaquine
on transmission. In these models, costs and outcomes are
linked to information on disease progression to produce
incremental cost-effectiveness ratios, such as the cost per
DALY averted or the cost per infection averted.
These models can be used to look at whether G6PD
testing is cost-effective for a given population where
either P. vivax infections are not being treated with primaquine or where primaquine is given without a G6PD
test. In areas where primaquine is not currently being
prescribed, a cost-effectiveness model will be important
to demonstrate the long-term impact of primaquine on
recurrences. Where primaquine is currently prescribed
without G6PD testing, economic modelling could weigh
the likelihood of haemolytic events against the burden of
disease caused by recurrent vivax episodes. If haemolytic
events are rare, it may be more economical to distribute
primaquine without G6PD testing; however, medical staff
must be comfortable implementing this policy choice.
If health care providers have ethical concerns and are
unwilling to take this risk, the economic justifications are
not relevant.
Economic models could also be used to evaluate which
of the aforementioned screening tests and strategies
(Figs. 1, 2, 3) would be most cost-effective in a given setting. The biosensor and RDT tests have different diagnostic accuracies and costs. Instead of simply looking
at which test is least expensive, an economic model will
synthesize the evidence concerning the epidemiology of
vivax and the prevalence and variant of G6PD deficiency
to determine which strategy will provide the most costeffective option in different settings. This evidence can
enable the available malaria funding to be allocated more
strategically.
Parameter values

Information needed for these models includes the prevalence of G6PDd in the population testing positive for

vivax malaria, the probability of haemolysis or death
when primaquine is given to a G6PD deficient individual, the probability of relapse if given or not given primaquine, adherence to primaquine treatment, and the
costs of all screening and treatment components. While
the cost of a G6PD test is often set low by manufacturers,
the cost to the healthcare provider is often inflated due to
procurement and logistics. This will need to be investigated by detailed costing research or through a sensitivity
analysis in the model. Other costs that need better characterization are those for clinical care of vivax cases, and
those for the management of severe haemolytic events
[46]. At this point, limited information exists on many of
the parameters needed to populate an economic model;
moreover, a number of these parameters are likely to vary
by setting. Further research is needed to reduce uncertainty and make these models informative.
In the future, economic modelling might capture wider
implications of G6PD testing in other disease areas.
G6PD deficiency is a common disorder and many other
widely used drugs can cause haemolysis in G6PD deficient individuals. More data would be needed to populate
such a model but this could lead to further economic justification for the implementation of G6PD testing.
Health system integration: a review of four countries

A critical component to broader access and use of G6PD
diagnostics is their integration into public health systems.
Countries face a number of considerations when discussing implementation of a G6PD test including: P. vivax
burden, elimination phase [47], income level, health
budget, health system capacity to implement a new product and degree of training required for relevant staff.
Using these factors, four countries (Bangladesh, Cambodia, Malaysia, and the Philippines; Tables 3, 4), across
a variety of income, malaria burden and health capacity
levels are reviewed here to assess the possibility and need
to implement routine G6PD testing.
Malaysia has achieved a substantial reduction in malaria
cases over the past several years, with 3850 cases reported

Table 3 Background Country Information
Bangladesh

Cambodia

Malaysia

Philippines

PQ is used for radical treatment of P.vivax (in guidelines) Yes (2008)

Yes (2015)

Yes

Yes (2007)

G6PD test is a requirement before treatment with PQ

No

Yes (2015)

Yes

Yes (2011)

Directly observed treatment with PQ is undertaken

No

No

Yes

Yes (2010)

# of confirmed malaria cases (all types) (year)

3864 (2013)

21,309 (2013)

3850 (2013)

6514 (2013)

% P. vivax

13 %

45 %

8%

20 %

Treatment for vivax?

Cq + PQ 0.25 mg/kg DHA-PPQ + PQ 0.25 mg/kg CQ + PQ 0.5 mg/kg CQ + PQ 0.5 mg/kg
(14 days)
(14 days)
(14 days)
(14 days)

Target Elimination Date

2030

Source: WHO World Malaria Report 2014 and APMEN

2025

2020

2020
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Table 4 Background information malaria screening and treatment
Questions

Bangladesh

Cambodia

What are the current screening
procedures for Pv?

Microscopy and RDT at health
facilities and community level

Microscopy and Microscopy
RDT at health
facilities, RDT
at communitylevel

Microscopy and RDTs. RDTs in rural health
facilities by trained barangay health
workers (BHWs). Microscopy in municipal
health clinics and gov’t hospitals. Trained
BHWs can also conduct microscopy

Active, passive, mass test or treat Both active and passive case
(MSAT), focused test and treat
detection. Focused test and
(FSAT)
treat in pre-elimination areas

Passive case
Active and
detection,
passive case
some active
detection
detection with
research. No
MSAT or FSAT

Passive case detection, some active detec‑
tion

Is G6PD testing mandatory? Is
it recommended prior to PQ
administration?

Not mandatory

Mandatory
Mandatory test‑ Testing is recommended
testing and
ing prior to PQ.
recommended
All newborns
prior to PQ
tested at birth

If G6PD testing is not manda‑
tory, are their alternative
procedures in place to assess
and monitor risk of posttreatment haemolysis? Are
patients monitored treatment
adherence?

Patient is advised to report hae‑
molysis. Follow ups are done
by NGO-PR (BRAC supported
consortium) at day 3, 7, and 14

No monitoring
system in
place

Who performs the majority of
screening activities?

Outreach Lab: Lab tech (NGO)
Lab tech, nurse,
Community Clinic: community
or community
health care provider (CHCP)
health worker
Union sub-centers: medical
officer, health assistant (GoB)
Field Level: Health Assistant (GoB)
or Shastho Kormi/Shastho
Shebika (NGO)
Medical officer at the District,
Upazila and Tertiary facility level

in 2013, mostly concentrated in the Sabah and Sarawak
regions of the country and the Central Highlands of
Western Malaysia [47]. The country aims for elimination
by 2017 and certification by 2020 [48]. Malaysia has had
on-going malaria control and elimination strategies since
the 1960s with original efforts at control beginning at the
start of the 20th century. Currently, Malaysia uses internal budgeting to supply the resources necessary to combat
malaria [48]. G6PD deficiency has been tackled through
extensive use of the FST and G6PD deficiency tests are
integrated into newborn screening programmes [49].
G6PD status is recorded and kept at the village and hospital level so that appropriate treatment can be provided
to patients. A single FST costs an estimated $0.28 per test
and $140 for the FST specific equipment (national malaria
control programme, personal communication) within the
country. Malaysia maintains FST kits at all hospitals and
health clinics. All malaria cases diagnosed in the country
are admitted to a hospital. Malaysia provides in-patient
care to P. vivax malaria patients and 14 days of 0.25 mg/
kg bw primaquine is provided to people with intermediate FST results (mild G6PD deficiency) compared to the
0.5 mg/kg bw to G6PD normal patients. Concerns over

Malaysia

Philippines

Patients are
monitored

Patients are advised to report haemolysis.
Treatment adherence is supposed to be
monitored by BHW. No monitoring of
haemolysis

Medical lab
techs and
nurses

MDs at clinics and hospitals
Licensed midwives or BHW at rural health
facilities

the need for observation of patients for adverse haemolytic events is limited and the exclusive use of a qualitative
test format seems justified.
Routine G6PD testing in the Philippines started in 1998
in the context of a comprehensive new born screening
programme and became mandatory in 2004. While the
Philippine government now finances 39 % of the antimalaria budget, with expectations to increase government budget coverage to 57 % from 2015 to 2017, the
bulk of the remaining funding comes from the Global
Fund [50] The country is seeking to integrate routine
G6PD testing into their national health insurance programme and cover costs through internal resources (Fe
Esperanza Espino, personal communication). Testing is
conducted with FST at 5000 newborn screening centers
across the country, with 20 confirmatory centers for all
identified G6PD deficient individuals by spectrophotometry. The Philippine records indicate that approximately
2 % of the population is G6PD deficient [51]. The Philippines is restructuring funding of G6PD testing, with the
imminent cessation of Global Fund support overlapping
with national efforts to ramp up their domestic capabilities. Given the Philippines moderate domestic resources
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and expected strain on budgets during the transition out
of Global Fund programmes in coming years, the country
may be able to optimize the use of both RDTs and biosensors. Qualitative RDTs may be ideal for quick, PoC testing by primary care providers and village health workers,
while biosensors could provide more detailed data for
potentially heterozygous females or customized therapy.
While the FST has successfully been implemented in the
country, the superior operational characteristics of the
Carestart RDT render the latter a potential candidate to
replace the FST in the long term.
Cambodia and Bangladesh are not testing G6PD status on a routine basis [52]. In light of the haemolytic risk
of primaquine Cambodia only recently recommended
single dose primaquine treatment in P. falciparum cases
without G6PD testing [29], while Bangladesh provides
primaquine for radical cure on a regular basis. In the
absence of alternative drugs to primaquine for hypnozoitocidal treatment Cambodia will eventually need to
include the drug in its treatment schedules in order to
pursue malaria elimination from the country [6]. Cambodia will only make primaquine radical cure for vivax
available when it can test reliably for G6PDd.
Following current WHO guidelines [8] the practice of
providing radical cure without routine G6PD testing calls
for a comprehensive risk—benefit analysis within Bangladesh, surveys to assess the local prevalence of G6PDd are
under way in parts of the country [51].

Additional files

Discussion and conclusion
The potential risks of 8-aminoquinoline therapy in the
small subpopulation of G6PD deficient vivax patients
have hindered the appropriate treatment of the large
majority of vivax patients. The availability of affordable
PoC tests for G6PDd is essential to detect at-risk patients
and to optimize the management of vivax malaria. New
G6PD tests are becoming available which may be able
to help calibrate the most appropriate 8-aminoquinoline regimen for patients with vivax malaria. A quantitative, easy to use and handheld test device that can also
provide a haemoglobin concentration would add great
value. Current qualitative RDT formats can reliably classify hemizygous males and homozygous females, but
may fail to correctly diagnose heterozygous females with
intermediate G6PD activity. Nevertheless the format of a
qualitative test is appealing, due to the similarity of the
product to malaria RDTs, its ease of use and a performance comparable to the most routinely used test, the
FST.
The roll out of G6PD testing will have implications
in terms of costs. It will be important to understand
these costs with different product concepts having different cost structures which will be defined by applied
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treatment algorithms, local P. vivax epidemiology and the
local health system. Much of the data needed for these
analyses are not yet available. Future research should
include data collection appropriate for use in cost-effectiveness studies, which will be useful to inform different
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With increasing availability of PoC tests for G6PDd
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